Author

P. A. Kenny

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

K. A. Lofgren· 3 shared S. Sreekumar· 2 shared C. S. Richmond· 1 shared E. C. Jenkins· 1 shared K. J. Ernzen· 1 shared M. A. Girtman· 1 shared N. C. Reker· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

7 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. A. Lofgren

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mammary-specific ectopic expression of mutant human GATA3 did not potentiate medroxyprogesterone acetate-driven mouse mammary tumorigenesis

K. A. Lofgren, P. A. Kenny

This study investigates whether mutant GATA3 expression synergizes with medroxyprogesterone acetate to drive mammary tumorigenesis in mice, finding no increased tumor incidence.

bioRxiv · Jan 3, 2023 · PreprintCancer Biology

Pan-cancer distribution of cleaved cell-surface Amphiregulin, the target of the GMF-1A3 antibody drug conjugate

K. A. Lofgren, N. C. Reker, S. Sreekumar, P. A. Kenny

The paper evaluates cleaved Amphiregulin levels in 370 tumor specimens across 10 types, showing high expression in breast, prostate, liver, and lung cancers.

bioRxiv · Mar 10, 2022Cancer Biology

The MKRN1-BRAF exon4-exon9 fusion is a targetable oncogenic driver

M. A. Girtman, C. S. Richmond, P. A. Kenny

The paper identifies MKRN1-BRAF fusion as an oncogenic driver in colorectal cancer and shows it is sensitive to trametinib.

bioRxiv · Jul 22, 2021 · PreprintCancer Biology

Anti-tumor efficacy of an MMAE conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer

K. A. Lofgren, S. Sreekumar, E. C. Jenkins, K. J. Ernzen, P. A. Kenny

This study develops an antibody drug conjugate targeting a cleaved Amphiregulin epitope, showing efficacy in breast cancer models and potential as a companion diagnostic.

bioRxiv · Jul 7, 2021Cancer Biology